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Abstract: The optical redox ratio (fluorescence intensity of NADH divided 
by that of FAD), was acquired for a panel of breast cancer cell lines to 
investigate how overexpression of human epidermal growth factor receptor 
2 (HER2) affects tumor cell metabolism, and how tumor metabolism may 
be altered in response to clinically used HER2-targeted therapies. Confocal 
fluorescence microscopy was used to acquire NADH and FAD auto-
fluorescent images. The optical redox ratio was highest in cells 
overexpressing HER2 and lowest in triple negative breast cancer (TNBC) 
cells, which lack HER2, progesterone receptor, and estrogen receptor (ER). 
The redox ratio in ER-positive/HER2-negative cells was higher than what 
was seen in TNBC cells, but lower than that in HER2 overexpressing cells. 
Importantly, inhibition of HER2 using trastuzumab significantly reduced the 
redox ratio in HER2 overexpressing cells. Furthermore, the combinatorial 
inhibition of HER2 and ER decreased the redox ratio in ER+/HER2+ breast 
cancer cells to a greater extent than inhibition of either receptor alone. 
Interestingly, trastuzumab had little impact upon the redox ratio in a cell 
line selected for acquired resistance to trastuzumab. Taken together, these 
data indicate that the optical redox ratio measures changes in tumor 
metabolism that reflect the oncogenic effects of HER2 activity within the 
cell, as well as the response of the cell to therapeutic inhibition of HER2. 
Therefore, optical redox imaging holds the promise of measuring response 
and resistance to receptor-targeted breast cancer therapies in real time, 
which could potentially impact clinical decisions and improve patient 
outcome. 
© 2011 Optical Society of America 
OCIS codes:  (170.1790) Confocal microscopy; (170.2520) Fluorescence microscopy; 
(170.1530) Cell analysis; (170.1610) Clinical applications. 
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1. Introduction 
The course of breast cancer treatment increasingly relies on the molecular phenotype of the 
tumor. For example, breast cancers that overexpress the estrogen receptor (ER) are often 
treated with ER-antagonists (e.g., tamoxifen, fulvestrant), while those that overexpress human 
epidermal growth factor receptor 2 (HER2) are often treated with HER2-inhibitors (e.g., 
trastuzumab, lapatinib). HER2 overexpressing tumors display aggressive cancer progression 
[1] and account for approximately 25% of all breast cancer patients. Treatment with 
trastuzumab (a monoclonal antibody which binds HER2) and lapatinib (a dual tyrosine kinase 
inhibitor that binds both HER2 and the epidermal growth factor receptor) has been shown to 
prolong survival in  patients with HER2 overexpressing breast cancers [2–4]. Due to the 
importance of choosing the correct treatment for breast cancer patients, breast tumors are 
routinely screened for expression of ER and HER2. Currently, ER and HER2 expression are 
determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). 
Unfortunately, approximately one-third of breast tumors that overexpress HER2 do not 
respond to trastuzumab and lapatinib therapy [4]. Similarly, only 57% of patients with ER-
positive breast cancers respond to tamoxifen therapy [5]. However, there are reasons to 
remain optimistic, as novel therapeutics are in development to overcome clinical resistance to 
these therapeutic inhibitors [6]. Early identification of those cancers that respond to targeted 
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treatment and will improve the clinical outcomes of breast cancer patients. 
Methods currently under development to determine tumor response to therapy include 
positron emission tomography (PET), x-ray computed tomography (CT) and magnetic 
resonance imaging (MRI) [7–9]. Evidence that tumor response to targeted inhibitors can be 
visualized was demonstrated with the use of fluoro-deoxyglocose (FDG)-PET, which is 
capable of detecting focused areas of high glucose uptake that are often seen in solid tumors. 
A preliminary clinical study of lapatinib-treated breast cancers showed changes in tumor 
metabolism after 1 month of lapatinib treatment [10]. Yet, these currently available 
technologies provide only low resolution images, are non-portable, and usually require the use 
of contrast agents. Given the high cost of these procedures, it is unlikely that these will be 
adopted as standard of care, underscoring the need for more efficient, accurate, and cost-
effective methods of identifying receptor expression and therapeutic response. 
Cellular metabolism is a potentially powerful biomarker for tumor analysis. Unlike normal 
cells that rely on oxidative phosphorylation to generate ATP, or that use glycolysis under 
anaerobic conditions, cancer cells often generate ATP through aerobic glycolysis [11]. 
Interestingly, signaling through the HER2 and ER pathways in breast cancer cells is thought 
to promote aerobic glycolysis. ER increases glucose transport and glycolysis [12,13]. 
Similarly, HER2 activated pathways may increase glucose transport into the cell and 
glycolysis [14,15]. HER2 signaling activates phosphatidyl inositol 3-kinase (PI3K) a major 
driver of aerobic glycolysis [16–19]. In mouse models of HER2 overexpressing breast cancer, 
trastuzumab and lapatinib inhibited PI3K activity and decreased glucose uptake as measured 
by FDG-PET imaging [20]. Conversely, breast tumor cells exhibiting resistance to HER2 
inhibitors display aberrantly increased PI3K activity and active hypoxia signaling despite the 
presence of adequate oxygen [18]. These studies suggest that differences in aerobic glycolysis 
may reflect not only oncogene-driven metabolic characteristics of the tumor cell, but also the 
effect of therapeutic inhibitors on tumor metabolism, and could therefore be used to 
distinguish tumors that are responsive to therapeutic inhibitors from those that are resistant. 
During oxidative phosphorylation, NADH is oxidized to NAD+ and FAD is reduced to 
FADH2. However, the process of glycolysis causes NAD+  to be reduced to NADH. 
Therefore, the ratio of NADH to FAD is a measurement of the balance between glycolysis 
(seen in tumor cells) and oxidative phosphorylation (seen in untransformed cells). NADH and 
FAD can be measured in situ using autofluorescence optical imaging techniques. The optical 
redox ratio (NADH fluorescence intensity divided by FAD fluorescence intensity) is a proven 
method of probing cellular metabolism and has been used to differentiate cancerous from non-
cancerous tissues in a variety of models including oral and breast cancer [21–27]. Ostrander et 
al. showed the optical redox ratio is also sensitive to ER expression in breast cancer cell 
cultures, and that treatment with tamoxifen decreased the optical redox ratio of tamoxifen-
sensitive cells, but not tamoxifen-resistant cells [27]. 
The purpose of this study was to determine the effect of HER2 overexpression on the 
metabolism of breast cancer cells as measured by the optical redox ratio. The hypothesis that 
HER2 overexpression influences cellular redox ratios independently of ER expression was 
tested. Additionally, the impact of HER2 inhibition on the redox ratio in HER2 
overexpressing breast cancer cells was measured. Finally, we determined if therapeutic 
resistance to HER2 inhibitors reflected on redox ratio measurements as a failure to reduce 
redox ratios in response to HER2 inhibition. HER2 overexpression was found to increase the 
redox ratio, independently of ER expression. While HER2 inhibition decreased the optical 
redox ratios in HER2 overexpressing cells, the HER2 inhibitor, trastuzumab, had no impact 
on redox ratios in trastuzumab resistant cells, despite continued overexpression of HER2. 
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2.1. Cell culture 
MCF10A cells were cultured in Mammary Epithelial Cell Growth Medium (MEGM, Lonza, 
Walkersville, MD) excluding the gentamycin-amphotericin B mix and supplemented with 100 
ng/ml cholera toxin and 1% penicillin:streptomycin. The BT474, MDA-MB-231, MCF7, and 
SKBr3 cells were grown in DMEM (Invitrogen, Carlsbad, CA), supplemented with 10% fetal 
bovine serum and 1% penicillin:streptomycin, hereafter referred to as DMEM+ . The resistant 
cell lines were grown in the DMEM+  at  levels of the corresponding drug to maintain 
resistance. The lapatinib resistant cells were grown at 1 µM lapatinib (LC Laboratories, 
Woburn, MA) concentration and the trastuzumab resistant cells were grown at 25 µg/ml. 
For imaging, all cell lines were plated at a density of 1x10
5 cells per 35 mm plate, 48 hours 
prior to imaging. Glass bottom dishes (MatTek Corporation, Ashland, MA) were used to 
allow live cell imaging on an inverted, confocal microscope. The trastuzumab and lapatinib 
resistant cell redox ratio was determined from cells grown in trastuzumab and lapatinib 
supplemented media. For the drug perturbation experiments, the responsive BT474 cells were 
fed the drug supplemented media 24 hours prior to imaging. For the trastuzumab perturbation 
of the trastuzumab resistant cells, the cells were fed the DMEM+ media for the first 24 hours 
after plating and the DMEM+ with trastuzumab for the second 24 hours. Drug concentrations 
of the media were selected to mimic therapeutic drug dosage in patients, 25 µg/ml for 
trastuzumab (VUMC Pharmacy, Nashville, TN) and 2 µM for tamoxifen (Sigma-Aldrich, St. 
Louis, MO) [20,28]. 
For the cyanide experiment to verify measurement of the redox ratio, MCF10A cells were 
plated at 1 x 10
5 cells per plate, 48 hours prior to imaging. Cells were imaged before the 
addition of cyanide. After 3 images from a plate were acquired, the cell media was exchanged 
for growth media supplemented with 4 mM NaCN (Sigma-Aldrich, St. Louis, MO). The cells 
were given one minute to react with the cyanide; then, three different places of each plate 
were imaged. 
Proliferation rates of MCF10A, MCF7, and BT474 cells were determined by antibody 
labeling of cells grown on parallel imaging plates. Mitotic cells were first marked using a 
Phospho-Histone H3 (Ser10) antibody (Cell Signaling Technology, Danvers, MA). Then, 
labeling of the primary antibody with Alexa Fluor 488 goat anti-rabbit IgG antibody 
(Invitrogen, Carlsbad, CA) allowed counting by flow cytometry of the highly fluorescent 
mitotic cells and the less-fluorescent unlabeled cells. The percentage of proliferating cells was 
determined by dividing the number of highly fluorescent cells into the total number of cells 
counted. 
2.2. Verification of ER and HER2 expression 
Cells were homogenized in ice-cold lysis buffer [50 mM Tris pH 7.4, 100 mM NaF, 120 mM 
NaCl, 0.5% NP-40, 100 µM Na3VO4, 1X protease inhibitor cocktail (Roche)], sonicated for 
10 s at 4°C, 13,000 x g for 5 min. Protein concentration was determined using the BCA assay 
(Pierce). Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
Membranes were blocked in 3% gelatin in TBS-T [Tris-buffered saline, 0.1% Tween-20) for 1 
h, incubated in primary antibody in 3% gelatin for 2 h at room temperature, washed with 
TBS-T, incubated in HRP-conjugated anti-rabbit or anti-mouse IgG, washed with TBS-T, and 
then developed using ECL substrate (Pierce). The following primary antibodies were used: 
ErbB2 (HER2) (Neomarkers, InVitrogen; 1:2000); ER-alpha (Santa Criz Biotechnologies; 
1:1000); beta actin (Sigma-Aldrich; 1:5000). 
2.3. Confocal imaging 
Images were acquired using an Olympus FV-1000 Inverted Confocal Microscope with a 
40X/1.3 NA oil-immersion objective. Confocal microscopy was chosen over widefield 
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measurement. Additionally, the redox ratio is sensitive to measurement volumes and confocal 
microscopy ensures that the NADH and FAD signals can be co-registered to the same volume. 
For NADH fluorescence, the cells were excited at 405 nm and 410-510 nm emission was 
collected. FAD was excited at 488 nm and 500-600 nm emission was collected. The two 
images were acquired simultaneously, with NADH and FAD acquired sequentially for each 
pixel. A pixel dwell time of 2 µs was used. Each line was averaged 4 times to reduce noise. A 
single 1024x1024 pixel image required 39.0 s to acquire. To ensure the cells were not 
photobleaching, two images of the same field of view were acquired consecutively with no 
significant change in average pixel intensity. Settings for the gain, offset, and pinhole were 
maintained across all imaging sessions. To account for daily variations in laser power or 
instrumentation instability, the images were normalized to MCF10A cell measurements 
acquired during each imaging session. Each plate was imaged at 3 different, non-overlapping 
locations. 
2.4. Image analysis 
The optical redox ratio, NADH fluorescence intensity divided by FAD fluorescence intensity, 
was computed for each cell in the image using ImageJ software (NIH). The fluorescence 
signal of non-cellular regions, or background signal, was removed to ensure the fluorescence 
comparisons were made only for the cells. NADH and FAD used for cellular metabolism are 
contained within the cytoplasm and mitochondria, and the fluorescence signal from the 
nucleus is not involved in cellular metabolism. Therefore, the fluorescence signal from the 
nucleus was also removed to ensure isolation of metabolic NADH and FAD and eliminate the 
possibility of nuclear size as a confounding factor. Next, a NADH/FAD per pixel image was 
computed and the redox ratio for each cell in the image was determined. The average redox 
ratio value from all cells in each image was computed and normalized to the corresponding 
session's MCF10A measurement. Standard error was computed from the mean redox ratio 
value across all images from each cell line. A rank sum test was used for all statistical 
comparisons. 
3. Results 
The optical redox ratio of a panel of human breast-derived cell lines with varying expression 
of ER and HER2 were studied (Table 1, Fig. 1). MCF10A, a non-cancerous breast cell line 
with negligible or low expression of ER and HER2 was used as a control for each analysis. 
To verify the use of optical imaging to  measure the redox ratio, cyanide was used to 
disrupt the electron transport chain, thus preventing the conversion of NADH to NAD+ [29]. 
As predicted, MCF10A cells treated with cyanide exhibited increased NADH fluorescence (p 
< 0.01, Fig. 2) and decreased FAD fluorescence (p < 0.05; Fig. 2). Therefore, the redox ratio  
 
Table 1. Breast cancer cell lines with corresponding ER and HER2 expression 
Cell line  Cancerous  ER status  HER2 overexpression  n 
MCF-10A  Non-cancerous  –/low  –/low  30 
MDA-MB-231  Cancer  Negative  Negative  15 
MCF-7  Cancer  Positive  Negative  15 
BT-474  Cancer  Positive  Positive  15 
SKBr3  Cancer  Negative  Positive  15 
HR6 (Trastuzumab 
Resistant BT-474) 
Cancer  Positive  Positive  15 
BT-LR (Lapatinib 
Resistant BT-474) 
Cancer  Positive  Positive 
15 
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Fig. 2). These results confirm that our optical imaging methods accurately reflect the balance 
between glycolysis and oxidative phosphorylation, and can be used to assess the metabolic 
state of tumor cells. 
 
Fig. 1. Western blot analysis demonstrates overexpression of HER2 in the SKBR3 and BT474 
cells and expression of ER in the MCF7 and BT474 cells. 
 
Fig. 2. Addition of CN to MCF10A cells (n = 6) results in an increase in redox ratio and 
NADH fluorescence and a decrease in FAD fluorescence. Bar height represents mean and error 
bars represent SE. 
 
Fig. 3. Representative NADH, FAD, and redox ratio images for MCF10A, MDA-231, MCF7, 
BT474 and SKBr3 cells. Optical redox ratio increases with ER and HER2 expression. 
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Fig. 4. Quantitative representation (mean +/− SE) of the redox ratio values for the MCF10A (n 
= 30), MDA-MB-231 (n = 15), MCF7 (n = 15), BT474 (n = 15), and SKBr3 cells (n = 15). 
Redox ratio is elevated in cells overexpressing HER2. 
We used optical imaging to capture NADH and FAD fluorescence in five breast derived 
cell lines (Fig. 3): MCF10A (untransformed breast epithelial cells), MDA-MB-231 (ER-
/HER2-), MCF-7 (ER+/HER2-), SKBR3 (ER-/HER2+), and BT474 (ER+/HER2+). The 
fluorescence intensities were used to calculate the redox ratio per cell for each cell line (Fig. 
4). While ER-/HER2- MDA-MB-231 cells displayed a redox ratio that was similar to what 
was seen in untransformed MCF10A cells, redox ratios were  elevated in all other breast 
cancer cell lines (p < 0.005). ER+/HER2- breast cancer cell lines displayed elevated redox 
ratios (p<0.005), but not to the extent seen in HER2+ breast cancer cell lines (p<0.001). 
 
Fig. 5. Redox ratio divided by proliferation rate mean +/−SE for MCF10A (n = 30), MCF7 (n = 
15) and BT474 (n = 15) cells. 
Controlling for differences in rates of proliferation among the MCF10A, MCF7, and 
BT474 cells did not reduce the significance of the redox ratio results shown in Fig. 4. In fact, 
controlling for proliferation (redox ratio divided by proliferation rate for each cell line) 
increases the differences between these three cell lines (Fig. 5). 
The redox ratio of both the trastuzumab resistant cell line, HR6, and the lapatinib resistant 
cell line, BT-LR, was lower than the redox ratio for the responsive parental BT474 cells (Fig. 
6A). The HR6 cells are BT474-derived cells that continue to grow in the presence of 
trastuzumab [30]. Likewise, the BT-LR cells are BT474-derived cells that were selected in 
culture with increasing concentrations of lapatinib [31]. To investigate the contributions of the  
 
#156540 - $15.00 USD Received 13 Oct 2011; revised 2 Dec 2011; accepted 3 Dec 2011; published 9 Dec 2011
(C) 2011 OSA 1 January 2012 / Vol. 3,  No. 1 / BIOMEDICAL OPTICS EXPRESS  82 
Fig. 6. (A) The redox ratio (mean +/−SE) of responsive BT474 cells is different from the 
trastuzumab (HR6) and lapatinib (BT-LR) resistant cells (n = 15), and there was no change in 
the redox ratio of trastuzumab-resistant HR6 cells with trastuzumab-treatment. (B) The redox 
ratio of responsive BT474 cells decreased with tamoxifen (2 µM), trastuzumab (25 µg/ml), and 
tamoxifen + trastuzumab treatment (n = 15). 
ER and HER2 signaling pathways to the redox ratio, BT474 cells (ER+/HER2+) were 
exposed to the ER antagonist tamoxifen and the anti-HER2 monoclonal antibody trastuzumab, 
(Fig. 6B). Trastuzumab significantly decreased the redox ratio in ER+/HER2+ breast cancer 
cells (p<0.001; Fig. 6B). Similarly, tamoxifen resulted in a decrease in redox ratio in the same 
cells (p<0.001, Fig. 6B). The combination of tamoxifen with trastuzumab decreased the redox 
ratio in BT474 cells (ER+/HER2+) to a greater extent than single agent tamoxifen (p<0.001) 
or trastuzumab (p<0.001; Fig. 6B). Interestingly, treatment of HR6 cells with trastuzumab did 
not cause any alterations in the redox ratio (Fig. 6A). It is difficult to fully eliminate the 
influence of lapatinib on the BT-LR cells; and therefore, outside the scope of this paper to 
robustly perform a comparison of pre- and post- lapatinib treatment in these cells. 
4. Discussion 
The selective use of aerobic glycolysis over oxidative phosphorylation by cancer cells has 
been known for over a century. We and others have shown that this characteristic of cancer 
cells can be monitored in situ using optical imaging to measure the redox ratio, or the ratio of 
glycolysis to oxidative metabolism. Furthermore, we show that “driver” oncogenes in breast 
cancer cells also drive aerobic glycolysis in these cells. Specifically, HER2 activity was 
required for maximal aerobic glycolysis in breast cells overexpressing HER2, while ER 
signaling was required for aerobic glycolysis in ER+  breast cancer cells. These results 
demonstrate the effect of the HER2 and ER signaling pathways on cancer cell metabolism, as 
measured by the optical redox ratio. These data support the conclusion that optical imaging of 
redox ratios can be used to measure the tumor cell response to therapeutic inhibitors in situ. 
Finally, using HER2 overexpressing breast cancer cells with acquired resistance to HER2 
inhibitors, we demonstrated that loss of oncogene dependence was reflected in the optical 
redox ratio measurement, such that HER2 inhibitors failed to decrease the redox ratio in a 
resistant cell line. Therefore, these findings could be applied to future studies using optical 
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development that would significantly inform clinical decisions regarding therapeutic strategies 
used to treat patients with HER2-positive breast cancers. 
While this is the first study to correlate HER2 overexpression and activity to the redox 
ratio, a previous study similarly determined that ER+ breast cells exhibited a higher optical 
redox ratio than ER-negative cells [27]. The previous study differs from the results presented 
herein because the previous study suggested that MCF7 cells (ER+/HER2-) exhibited  a 
similar redox ratio to BT474 cells (ER+/HER2+). However, our results suggest that BT474 
cells have significantly higher redox ratios than MCF7 cells. Several experimental factors 
could explain the differing results, including different excitation wavelengths for NADH, 
differing emission filters, and different growth media. Ostrander et al. used media 
supplemented with 5% FBS versus 10% used in our studies, which may have increased 
cellular proliferation in our experiments versus those described earlier, thus affecting tumor 
cell metabolism [32]. However, when controlling for cell proliferation, the difference in the 
redox ratio between MCF7 and BT474 cells increased in the current study (Fig. 5). Different 
emission filters capture different areas of the NADH and FAD emission curves, affecting 
absolute fluorescence intensity which may change the redox ratio. The results of the cyanide 
experiment ensure measurement of NADH and FAD fluorescence for this study (Fig. 2). 
The results show that redox ratios in triple-negative MDA-MB-231 cells were similar to 
what was seen in MCF10A cells, which was less than the redox ratio seen in HER2+ or ER+ 
breast cancer cells. Triple-negative breast cancers (TNBC) lack HER2, ER, and PR, so they 
are difficult to target and no molecular targeted therapies exist for these breast cancers. 
Several FDG-PET studies in TNBC, ER+ , and HER2+ tumors report high variability in the 
glucose uptake of triple negative cells [33,34]. Note that FDG-PET imaging illuminates 
different aspects of cellular metabolism (glucose uptake) than the optical redox ratio (relative 
concentrations of NADH and FAD, end products of metabolism). However, these previous 
reports indicate that the metabolism of TNBC is complex and heterogeneous, so a full 
characterization of this tumor subtype will likely require a more concentrated study. 
The highest redox ratios were measured in breast cancer cell lines with HER2 
overexpression. The higher redox ratio of HER2 overexpressing cells suggests that the HER2 
pathway may affect cellular metabolism. Indeed, studies have found increased concentrations 
of glucose transporters and glycolytic enzymes present in HER2 overexpressing cells versus 
cells with low expression of HER2 [14,15]. 
We found that HER2 inhibition with trastuzumab decreased the redox ratio of HER2 
overexpressing breast cancer cells (p< 0.001, Fig. 6B). This is consistent with several studies 
reporting reduced glucose uptake, decreased lactate secretion, and decreased glycolysis, in 
responsive HER2 overexpressing breast cancer cells treated with trastuzumab [35,36]. 
Treatment with both trastuzumab and tamoxifen decreased the redox ratio of responsive 
BT474 cells to levels seen in the non-cancerous MCF10A cell line (Fig. 6B). These results 
suggest that both ER and HER2 signaling affects tumor cell metabolism in breast cancer cells. 
Mechanistic studies of receptor expression support this result. Cells expressing ER 
overexpress glucose transporters and have higher reported rates of glycolysis [12,13]. 
Similarly, HER2  overexpression is linked with increased glucose transport into cells and 
increased glycolysis [14,15]. 
Innate and acquired resistance to HER2 inhibitors limits their current clinical success. 
Nearly all HER2-amplified breast cancers treated with trastuzumab or lapatinib will ultimately 
develop resistance to these targeted inhibitors. We examined trastuzumab-resistant cells, 
demonstrating that trastuzumab failed to reduce the redox ratio in the resistant cells (Fig. 6A). 
These results are the first  of its kind, but are consistent with an FDG-PET study of 
trastuzumab responsive and non-responsive breast cancer xenographs, demonstrating that 
HER2 inhibitors failed to reduce FDG uptake in those tumors whose growth was unaffected 
by trastuzumab [37]. Interestingly, the redox ratio of the trastuzumab and lapatinib resistant 
#156540 - $15.00 USD Received 13 Oct 2011; revised 2 Dec 2011; accepted 3 Dec 2011; published 9 Dec 2011
(C) 2011 OSA 1 January 2012 / Vol. 3,  No. 1 / BIOMEDICAL OPTICS EXPRESS  84cells are different from the pre-treatment redox ratio value of responsive BT474 cells, p<0.001 
(Fig. 6A). These results open up the possibility of screening HER2-inhibitor resistance with 
the optical redox ratio. 
Future in vivo studies are needed to verify the influence of ER and HER2 expression on 
cellular metabolism. Increasing research is elucidating the importance of metabolism in 
cancer cells and its relationship with drug resistance. Here, upon treatment with receptor 
targeted therapies, the change in metabolism of resistant cells is shown to be negligible, while 
the metabolism of responsive cells is significant. Additionally, basal redox ratios are different 
in resistant versus responsive cells. Therefore, cellular redox ratios may prove an invaluable 
tool for research and clinical identification of receptor expression, tumor resistance to targeted 
therapies, and for monitoring treatment efficacy. 
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